Bruyneel Marie, Sersté Thomas
Sleep Unit, Department of Pneumology, Centre Hospitalier Universitaire Saint Pierre, Université Libre de Bruxelles, Brussels, Belgium,
Department of Hepato-gastroenterology, Centre Hospitalier Universitaire Saint Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Nat Sci Sleep. 2018 Nov 2;10:369-375. doi: 10.2147/NSS.S186665. eCollection 2018.
Sleep-wake disturbances are common in liver cirrhosis and associated with impaired quality of life. The most common abnormalities are insomnia (difficulties falling asleep and maintaining sleep, or unrefreshing sleep), excessive daytime sleepiness, and sleep-wake inversion (disturbances of circadian rhythmicity). The underlying pathophysiological mechanisms for sleep disturbances in cirrhosis are complex and may include disturbed metabolism of melatonin and glucose, alterations in thermoregulation, and altered ghrelin secretion profiles. Sleep-wake abnormalities are related to the presence of hepatic encephalopathy (HE) and improvement in sleep parameters can be observed when HE is properly managed. A few non-specific treatments for sleep-wake abnormalities have been tried with encouraging results for hydroxyzine and modafinil. However, due to the potential for medication toxicity in these disabled patients, further studies are needed to address the potential role of non-drug therapies in this population (eg, cognitive behavioral therapy, mindfulness, yoga) that have demonstrated usefulness in insomnia disorders.
睡眠-觉醒障碍在肝硬化患者中很常见,且与生活质量受损有关。最常见的异常情况是失眠(入睡困难、难以维持睡眠或睡眠后无恢复感)、日间过度嗜睡和睡眠-觉醒颠倒(昼夜节律紊乱)。肝硬化患者睡眠障碍的潜在病理生理机制很复杂,可能包括褪黑素和葡萄糖代谢紊乱、体温调节改变以及胃饥饿素分泌谱改变。睡眠-觉醒异常与肝性脑病(HE)的存在有关,当HE得到妥善处理时,睡眠参数可得到改善。已经尝试了一些针对睡眠-觉醒异常的非特异性治疗方法,其中羟嗪和莫达非尼取得了令人鼓舞的效果。然而,由于这些失能患者存在药物毒性风险,需要进一步研究以探讨非药物疗法(如认知行为疗法、正念疗法、瑜伽)在该人群中的潜在作用,这些疗法已被证明对失眠症有效。